Status:
UNKNOWN
Hemolysis in Patients With Hereditary Spherocytosis (HS)
Lead Sponsor:
Wolfson Medical Center
Conditions:
Hereditary
Hemolysis
Eligibility:
All Genders
5+ years
Phase:
NA
Brief Summary
In the present study the investigators are going to explore the oxidative status of HS-RBC and its contribution to hemolysis
Detailed Description
The oxidative status of cells, which is determined by the balance between pro-oxidants, such as the reactive oxygen species (ROS), and antioxidants, is a major regulator of cellular functions. Impaire...
Eligibility Criteria
Inclusion
- patients \> 5 years
- with documented family history of HS
- patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
Exclusion
- non
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2011
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01201174
Start Date
September 1 2010
End Date
September 1 2011
Last Update
September 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wolfsson Medical Center
Holon, Israel,, Israel